With heightened interest in the category, it is vital that immunity products have credible scientific evidence and are marketed responsibly.
In this edition, we’ll shine the spotlight on the companies that are investing in gold-standard immunity trials and pushing the boundaries when it comes to emerging research across the industry, including those assessing potential adjunctive therapies in the fight against COVID-19. We’ll also be discussing how to translate high science into understandable communication for consumers, as well as looking at the practical challenges posed to research by the pandemic.
